http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 18 Feb 2026 09:21:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+18/26019119.html si-local-file:///var/storage/secattach/20260218/26019119.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+18/26019119.html Wed, 18 Feb 2026 09:21:00 -0500 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+18/26019119.html si-local-file:///var/storage/secattach/20260218/26019119.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+18/26019119.html Wed, 18 Feb 2026 09:21:00 -0500 NRSN O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 -0500 NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Corporate+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 -0500 NRSN NRSNW http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 -0500 NRSN NRSNW http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/FDA/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 -0500 NRSN NRSNW http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 -0500 NRSN NRSNW http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced extended survival data from its completed PARADIGM Phase 2b clinical trial of PrimeC in patients with amyotrophic lateral sclerosis. The analysis showed a statistically significant 65% reduction in the risk of death for patients receiving PrimeC compared to those initially assigned to placebo.</p><p>According to Kaplan-Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo. This represents a 14.9-month improvement in median survival.</p><p>A log-rank test comparing survival curves demonstrated statistical significance with a http://www.streetinsider.com/Hot+Corp.+News/NeuroSense+reports+65%25+death+risk+reduction+in+ALS+trial/26019033.html Wed, 18 Feb 2026 09:05:42 -0500 NRSN NRSNW http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/Press+Releases/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).</p> <div id="prni_dvprnejpg2863left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg2863left" style="width: 400px; height: 160px;" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p>The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in http://www.streetinsider.com/PRNewswire/NeuroSense+Announces+Statistically+Significant+65%25+Reduction+in+Risk+of+Death+and+Greater+than+14-Month+Median+Survival+Benefit+with+PrimeC+in+ALS/26019027.html Wed, 18 Feb 2026 09:05:00 -0500 H1Z NRSN NRSNW O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+13/26001205.html si-local-file:///var/storage/secattach/20260213/26001205.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+13/26001205.html Fri, 13 Feb 2026 16:35:00 -0500 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+13/26001205.html si-local-file:///var/storage/secattach/20260213/26001205.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+13/26001205.html Fri, 13 Feb 2026 16:35:00 -0500 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+09/25965964.html si-local-file:///var/storage/secattach/20260209/25965964.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+09/25965964.html Mon, 09 Feb 2026 09:30:00 -0500 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+09/25965964.html si-local-file:///var/storage/secattach/20260209/25965964.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Feb+09/25965964.html Mon, 09 Feb 2026 09:30:00 -0500 NRSN O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Australian+patent+for+PrimeC+drug+composition/25965896.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Australian Patent Office granted patent number 2022370513 for its PrimeC drug composition. The patent, titled "Compositions Comprising Ciprofloxacin and Celecoxib," provides protection through October 2042.</p><p>The Australian patent follows the company's previously granted U.S. patent 12,097,185 for the same composition. PrimeC is a fixed-dose oral therapy that combines ciprofloxacin and celecoxib in an extended-release formulation designed for neurodegenerative diseases including ALS and Alzheimer's disease.</p><p>"Securing patent protection in Australia, in addition to the already granted patent in the US, is an important step in executing our global IP protection strategy for PrimeC," said Alon http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Australian+patent+for+PrimeC+drug+composition/25965896.html Mon, 09 Feb 2026 09:20:41 -0500 NRSN http://www.streetinsider.com/Press+Releases/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html <div class="xn-content"> <p><i>Strengthens Global IP Portfolio for PrimeC Through 2042</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled <i>"Compositions Comprising Ciprofloxacin and Celecoxib," </i>representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.</p> <div id="prni_dvprnejpg93a4left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg93a4left" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p>The granted Australian patent, http://www.streetinsider.com/Press+Releases/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html Mon, 09 Feb 2026 09:20:00 -0500 NRSN O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html <div class="xn-content"> <p><i>Strengthens Global IP Portfolio for PrimeC Through 2042</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled <i>"Compositions Comprising Ciprofloxacin and Celecoxib," </i>representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.</p> <div id="prni_dvprnejpg93a4left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg93a4left" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p>The granted Australian patent, http://www.streetinsider.com/Press+Releases/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html Mon, 09 Feb 2026 09:20:00 -0500 NRSN O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html <div class="xn-content"> <p><i>Strengthens Global IP Portfolio for PrimeC Through 2042</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled <i>"Compositions Comprising Ciprofloxacin and Celecoxib," </i>representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.</p> <div id="prni_dvprnejpg93a4left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg93a4left" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p>The granted Australian patent, http://www.streetinsider.com/PRNewswire/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html Mon, 09 Feb 2026 09:20:00 -0500 NRSN O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html <div class="xn-content"> <p><i>Strengthens Global IP Portfolio for PrimeC Through 2042</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled <i>"Compositions Comprising Ciprofloxacin and Celecoxib," </i>representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.</p> <div id="prni_dvprnejpg93a4left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg93a4left" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1707291%2FNeuroSense_Therapeutics_Logo.jpg" /></div><p>The granted Australian patent, http://www.streetinsider.com/PRNewswire/NeuroSense+Expands+Global+IP+Protection+Strategy+With+Granted+Australian+Patent+Covering+PrimeC+Composition/25965890.html Mon, 09 Feb 2026 09:20:00 -0500 NRSN O.31364977